Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.10 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
HIMS and SRPT ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients
Sarepta Therapeutics shares are halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys. 
Via Benzinga
FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement
Via Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment. 
Via Benzinga
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
From Bernstein Liebhard LLP
Via GlobeNewswire
Retail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy
The update comes as Sarepta faces mounting regulatory scrutiny, including an ongoing FDA investigation and a recommendation from European regulators to reject approval of Elevidys. 
Via Stocktwits
Topics Death
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients. 
Via Benzinga
Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback
Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward. 
Via Stocktwits
Topics Death
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys. 
Via Investor's Business Daily
Topics Death
Sarepta Therapeutics, Inc. Class Action: Levi &amp; Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
From Sarepta Therapeutics, Inc.
Via Business Wire
Friday's pre-market session: top gainers and losers
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies.
Sarepta stock is now trading at a nine-year low as the debacle with its gene therapy, Elevidys, continues. 
Via Investor's Business Daily
Topics Death Workforce
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Sarepta Therapeutics, Inc. Class Action: Levi &amp; Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Is This Stock a Buy After Soaring by 20% in 1 Day?
Via The Motley Fool
Topics Death
Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label
Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and valuation cuts. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.